Benchmark Holdings (BMK) AI Stock Analysis

• Market Cap: £172.24M
• Dividend Yield: N/A
• Average Volume (3M): 204.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 800
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 742,423,100
• 10 Day Avg. Volume: 116,485
• 30 Day Avg. Volume: 204,508
• PEG Ratio: 0.02
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 71.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £24.50
• Price Target Upside: 19.80% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: 23.50p ▲(14.91%Upside)

The overall stock score reflects mixed financial performance and a bearish technical outlook, offset by positive corporate events that suggest potential future growth. While operational challenges persist, strategic changes and shareholder support provide a more optimistic long-term view.

Benchmark Holdings Business Overview & Revenue Model

Company Description

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, rest of the Europe, and internationally. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products to the aquaculture market. Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.

How the Company Makes Money

Benchmark Holdings generates revenue through the sale of its products and services across its three main sectors. In the Genetics sector, the company makes money by providing genetic material and breeding services to enhance the traits of farmed fish, which can lead to higher yields and better resistance to disease. The Advanced Nutrition sector contributes to revenue through the sale of high-performance diets and nutrition products designed to improve the growth and health of farmed fish. In the Health sector, Benchmark earns income from the development and sale of vaccines, medicines, and health management solutions that help prevent and treat diseases in aquaculture. Additionally, Benchmark collaborates with various industry stakeholders and partners to enhance its product offerings and expand its market reach, thus contributing to its overall earnings.

Benchmark Holdings Financial Statement Overview

Summary

Benchmark Holdings presents a mixed financial picture. Despite a healthy equity position and improved cash flow management, ongoing operational losses and declining revenues are concerning. Strategic actions are needed to enhance financial stability.

Income Statement

Benchmark Holdings has experienced fluctuating revenues, with a significant decline in the TTM period. The gross profit margin has deteriorated from prior years, and while there was a significant net income in the TTM period, it may be due to extraordinary items rather than operational efficiency. EBIT and EBITDA margins are negative, indicating ongoing operational challenges.

Balance Sheet

The company maintains a healthy equity position with a debt-to-equity ratio that suggests manageable leverage. However, the equity ratio has decreased over the years, reflecting increased liabilities. The TTM shows an improvement in cash positions, which enhances liquidity, but declining total assets over time could be concerning.

Cash Flow

Benchmark Holdings has improved its free cash flow in the TTM period, indicating better cash management. The operating cash flow to net income ratio suggests the company is generating cash efficiently relative to its reported income. However, consistent negative free cash flow in prior periods indicates past difficulties in generating cash.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	50.77M	90.36M	169.48M	158.28M	125.06M	105.56M
Gross Profit	24.26M	43.95M	86.75M	83.13M	65.58M	54.96M
EBITDA	-2.81M	3.96M	34.20M	28.35M	24.36M	14.34M
Net Income	46.00M	-39.46M	-23.15M	-30.45M	-11.58M	-22.77M
Balance Sheet
Total Assets	424.29M	384.90M	471.30M	526.57M	481.99M	489.04M
Cash, Cash Equivalents and Short-Term Investments	207.51M	23.09M	36.52M	36.40M	39.46M	71.61M
Total Debt	81.61M	72.07M	102.00M	110.14M	120.39M	109.16M
Total Liabilities	121.45M	160.63M	188.68M	203.29M	202.39M	193.59M
Stockholders Equity	302.83M	218.26M	276.40M	313.40M	271.71M	289.13M
Cash Flow
Free Cash Flow	2.54M	-1.92M	13.22M	-1.91M	-16.93M	-15.47M
Operating Cash Flow	6.81M	2.00M	20.00M	10.81M	5.79M	-4.06M
Investing Cash Flow	180.44M	-2.83M	-5.27M	-11.22M	-23.09M	30.38M
Financing Cash Flow	67.00K	-10.97M	-12.33M	-6.92M	-14.67M	30.13M

Benchmark Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BMK, the sentiment is Negative. The current price of 20.45 is below the 20-day moving average (MA) of 24.27, below the 50-day MA of 23.96, and below the 200-day MA of 28.39, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 17.91 is Positive, neither overbought nor oversold. The STOCH value of 59.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BMK.

Benchmark Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANCR	73 Outperform	£181.44M	33.67	5.04%	190.84%	-0.17%	592.46%
VLG	63 Neutral	£72.35M	99.15	1.00%	―	―	―
EAH	62 Neutral	£51.84M	30.72	1.99%	―	-4.37%	―
APH	59 Neutral	$355.92M	―	-5.04%	―	-1.02%	67.70%
BMK	54 Neutral	£172.24M	―		―	―	―
AGY	53 Neutral	£386.08M	―	-369.20%	―	4.50%	74.32%
Sector *	52 Neutral	kr5.63B	10.38	-63.86%	1.96%	27.11%	26.73%

Benchmark Holdings Corporate Events

Benchmark Holdings Completes Tender Offer, Cancels Shares

Benchmark Holdings announced the results of its Tender Offer, where 127,720,171 Ordinary Shares were purchased and will be canceled, returning approximately £31.9 million to shareholders. This move is part of Benchmark’s strategic plan to conclude discussions with Oslo Børs regarding the cancellation of its shares from Euronext Oslo, impacting the company’s trading and shareholder structure.

Benchmark Holdings Announces Strategic Board and Management Changes

Benchmark Holdings has announced significant changes to its board and management, effective from mid to late August 2025. Patrick Waty will take over as CEO, and Pierre Hugo will become CFO, among other board changes. These shifts are part of a strategic move following the company’s anticipated de-listing, potentially impacting its operational focus and stakeholder dynamics.

Benchmark Holdings Announces Strategic Delisting and Tender Offer

Benchmark Holdings has announced the approval of its proposals to return the majority of net proceeds from the sale of its Genetics Business to shareholders, delist from AIM and Euronext Growth Oslo, and re-register as a private limited company. The tender offer will open on July 3, 2025, and the delisting from Euronext Growth Oslo is expected to follow the completion of the tender offer. These strategic moves are aimed at streamlining operations and focusing on core business areas, potentially impacting shareholders and market positioning.

Benchmark Holdings Updates Total Voting Rights

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that its total issued share capital now consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission, impacting the calculation of shareholder interests.

Benchmark Holdings Updates Total Voting Rights

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that as of June 30, 2025, its total issued share capital consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission. The updated share capital figure will be used by shareholders to determine their interest or changes in their interest in the company.

Benchmark Holdings Secures Shareholder Approval for Strategic Resolutions

Benchmark Holdings announced that all resolutions at their General Meeting were approved, including a tender offer, de-listing, and re-registration. This approval signifies strong shareholder support and could impact the company’s strategic direction and market presence. Additionally, the company was informed of a recapitalization arrangement involving Mavenir Systems Inc., where the Chair of Benchmark, Nathan ‘Tripp’ Lane, is a board director.

Benchmark Holdings Reports £76m Profit, Plans Delisting and Capital Return

Benchmark Holdings reported a £76 million profit for the first half of 2025, primarily driven by the £90.9 million gain from the sale of its Genetics business. The company plans to return capital to shareholders and delist from AIM and Euronext Growth Oslo. Despite a 22% decline in group revenues from continuing activities, the company has shown improvements in Advanced Nutrition and maintained solid performance in its Health segment. The restructuring following the Genetics sale is expected to streamline operations and reduce costs, positioning Benchmark for future growth. The company is also preparing for the relaunch of Ectosan® Vet and CleanTreat® with a new land-based model.

Benchmark Holdings Adjusts Webcast Timing for Interim Results Announcement

Benchmark Holdings plc has announced a change in the timing of its Equity Development webcast for retail investors, which will now occur at 10.00am UK time on Thursday, 12 June 2025. This webcast is part of the company’s release of its unaudited interim results for the six-month period ending 31 March 2025. The change in schedule reflects the company’s commitment to engaging with its investors and stakeholders, potentially impacting investor relations and market perception.

Benchmark Holdings to Announce Interim Results on 12 June 2025

Benchmark Holdings plc has announced that it will release its unaudited interim results for the six-month period ending 31 March 2025 on 12 June 2025. The announcement will be accompanied by presentations for analysts, institutional investors, retail investors, and wealth managers, indicating the company’s commitment to transparency and engagement with its stakeholders.

Benchmark Holdings Announces Strategic Shift Post-Genetics Business Sale

Benchmark Holdings PLC has announced a series of proposals following the disposal of its Genetics Business, including the return of capital to shareholders and the cancellation of its shares from trading on AIM and Euronext Growth Oslo. The company plans to re-register as a private limited company and offer a tender for shareholders to realize their investments, with a special dividend planned post-tender. These moves aim to streamline operations and focus on future growth, with implications for shareholder structure and market presence.

Benchmark Holdings Confirms Stable Share Capital Structure

Benchmark Holdings PLC announced that as of 30 April 2025, its issued share capital consists of 741,505,672 ordinary shares, all with voting rights. This figure has remained unchanged since the previous announcement on 31 March 2025, and shareholders can use this number to calculate their interest in the company. This stability in share capital indicates a steady state in the company’s financial structure, which could reassure investors and stakeholders about the company’s current market position.